カテゴリ： GlobalData, アメリカ, 企業調査

Danaher Corp (DHR)：医療機器：M&Aディール及び事業提携情報

◆英語タイトル：Danaher Corp (DHR) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA904C7345
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：146
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Danaher Corp (Danaher) is a medical technology company which designs, manufactures and markets medical, professional, commercial and industrial products and services. It offers a wide range of testing instruments, communications solutions, water quality systems, medical diagnostics solutions, life science research tools, professional microscopes, dental products, product identification solutions, automation solutions and sensors and controls solutions. The company operates manufacturing, sales, distribution, service and administrative facilities in Europe, Australia, Asia and the Americas. The company distributes its products to its customers across the Americas; Europe, Middle East, Africa and Asia-Pacific through direct sales personnel and independent distributors. Danaher is headquartered in Washington DC, the US.

Danaher Corp (DHR) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Danaher Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 9
Danaher Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 10
Danaher Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 11
Danaher Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 12
Danaher Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 13
Danaher Corp, Medical Equipment, Deal Details 18
Asset Purchase 18
Beckman Coulter Acquires Clinical Microbiology Business from Siemens Healthcare Diagnostics 18
Devicor Medical Products Acquires Hydromark Breast Biopsy Marker Portfolio And Related Assets From Biopsy Sciences 20
Venture Financing 21
H2O TECH Secures Investment In Venture Financing 21
Partnerships 22
Leica Biosystems Enters into Licensing Agreement with Arno Therapeutics 22
Cell Signaling Technology Enters Into Licensing Agreement With Cepheid For Personalized Cancer Diagnostics 23
Smart Imaging Enters Into Licensing Agreement With Leica Microsystems 24
Prosolia Enters Into Licensing Agreement With AB Sciex For ORNL Analytical Technology 25
Thermo Fisher and Leica Microsystems Enter into Partnership 26
AB Sciex Enters into Co-Marketing Agreement with IROA Technologies 27
Leica Biosystems Enters into Distribution Agreement with Kub Technologies 28
Clearbridge Enters into Agreement with Leica Biosystems 29
Clearbridge BioMedics and Leica Biosystems Enter into Co-Marketing Partnership 30
SCIEX forms Joint Venture with Zhejiang Dian Diagnostics in China 31
Nobel Biocare Enters into Agreement with Dentalpoint 32
Grifols and Beckman Coulter Enter into Distribution Agreement 33
SpeeDx Enters into Distribution Agreement with Cepheid 34
Bayer Enters into Co-Development Agreement with Leica Biosystems 35
Novacyt Enters into Partnership with Cepheid 36
DiaSorin Enters into Agreement with Beckman Coulter 37
Devicor Medical Products Enters into Distribution Agreement with Endomagnetics 38
Leica Biosystems Enters into Co-Development Agreement with Merrimack Pharma 39
AB Sciex Enters into Agreement with QPS Holdings 40
Leica Biosystems Enters into Agreement with Advanced Cell Diagnostics 41
Cepheid, MedImmune and Combacte Enter into Agreement 42
AB Sciex Enters into Co-Marketing Agreement with Pressure BioSciences 43
Cepheid Enters into Agreement with Foundation for Innovative New Diagnostics 44
Sidney Kimmel Cancer Center Enters into Agreement with Cepheid 45
RareCyte Enters into Co-Marketing Agreement with Leica Biosystems 46
Vomaris Innovations Enters into Distribution Agreement with Metrex Research 47
DiaSorin Enters into Distribution Agreement with Beckman Coulter Diagnostics 48
Ab Sciex Enters into Co-Marketing Agreement with Hepregen 49
NanoCellect Biomedical Enters into Co-Development Agreement with Invetech 50
Bio-Rad Labs Extends Agreement with Beckman Coulter Diagnostics 51
NeoStem Enters into Co-Development Agreement with Invetech 52
Leica Biosystems Nussloch Partners with NovoPath 53
Leica Biosystems Nussloch Partners with Mayo Clinic 54
Foundation for Innovative New Diagnostics Enters into Agreement with Cepheid and Rutgers 55
Ab Sciex Enters into Co-Development Agreement with Dalton Pharma 56
Leica Biosystems Enters into Co-Marketing Agreement with Advanced Cell Diagnostics 57
Leica Biosystems Enters into Co-Development Agreement with Bristol-Myers Squibb 58
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 59
Devicor Medical Products Enters Into Distribution Agreement With Faxitron Bioptics For CoreVision 60
Invetech Enters Into Co-Development Agreement With Biocartis For Evalution 61
Arno Therapeutics Enters Into Co-Development Agreement With Leica Biosystems 62
Ab Sciex, Genedata And Leco Enter Into Agreement For Metabolomics Data Analysis Solution 63
Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 64
Leica Biosystems Enters Into Agreement With Aspera For Data Distribution Solution 65
CellaVision Expands Distribution Agreement With Beckman Coulter 66
Leica Biosystems And Synthon Biopharma Enter Into Agreement To Develop Companion Diagnostic Test For Targeted Cancer Therapies 67
Cepheid Enters Into Co-Development Agreement With Oregon Health and Science University 68
Galena Biopharma Enters Into Co-Development Agreement With Leica Biosystems 69
IRIS International Enters Into Distribution Agreement With Alifax 70
Leica Microsystems Enters Into Integration Agreement With Indica Labs 71
Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 72
Radisens Diagnostics Enters Into Co-Development Agreement With Beckman Coulter For HDR Detection Technology 73
Devicor Medical Products Enters Into Co-Marketing Agreement With Carbon Medical Technologies 74
Iris International Enters Into Distribution Agreement With Fisher HealthCare 75
Merger 76
Molecular Devices and ForteBio Complete Merger to Form Biologics Solutions 76
Equity Offering 77
Danaher Plans to Raise Funds through Public Offering of Securities 77
Debt Offering 78
Danaher Raises USD279.8 Million in Public Offering of Floating Rate Notes Due 2022 78
Danaher Raises USD671.6 Million in Public Offering of 1.2% Notes Due 2027 80
Danaher Raises USD500 Million in Public Offering of 1.65% Notes Due 2018 82
Danaher Raises USD500 Million in Public Offering of 3.35% Notes Due 2025 84
Danaher Raises USD500 Million in Public Offering of 2.4% Notes Due 2020 86
Danaher Raises USD500 Million in Public Offering of 4.375% Notes Due 2045 88
Danaher Raises USD500 Million in Public Offering of Notes Due 2017 90
Danaher Raises USD671 Million in Public Offering of 1% Notes Due 2019 92
Danaher Raises USD894.5 Million in Public Offering of 2.5% Notes Due 2025 94
Danaher Raises USD894.5 Million in Public Offering of 1.7% Notes Due 2022 96
Cepheid Completes Private Placement Of Notes Due 2021 For US$345 Million 98
Asset Transactions 100
GENEWIZ to Acquire Genomic Services Business of Beckman Coulter 100
Haemonetics Completes Acquisition Of Blood Collection, Filtration And Processing Product Lines From Pall For US$551 Million 101
Acquisition 103
Danaher to Acquire Integrated DNA Technologies 103
Danaher Acquires Phenomenex 104
Danaher Acquires Cepheid 105
Danaher Acquires Pall for USD13.8 Billion 107
Leica Microsystems to Acquire Bioptigen 109
Danaher Acquires 97% Stake in Nobel Biocare for USD2.17 Billion in Tender Offer 110
Leica Biosystems Nussloch Acquires Devicor Medical from GTCR 112
Leica Biosystems Acquires Kreatech Diagnostics 113
Leica Microsystems And Leica Biosystems Acquire Aotec Instrumentos 114
Quest Diagnostics Completes Sale Of HemoCue To Radiometer Medical For US$300 Million 115
Danaher Completes Acquisition Of 91.6% Stake In Iris International, Diagnostic Test Maker, For US$324 Million 117
Leica Biosystems Completes Acquisition Of Aperio Technologies 119
Beckman Coulter Acquires Blue Ocean Biomedical From Npe Systems 121
Pall Corporation Completes Acquisition Of ForteBio For US$142.5 Million 122
Danaher Corp – Key Competitors 124
Danaher Corp – Key Employees 125
Danaher Corp – Locations And Subsidiaries 126
Head Office 126
Other Locations & Subsidiaries 126
Business Unit 133
Recent Developments 134
Financial Announcements 134
Apr 19, 2018: Danaher Announces First Quarter 2018 Results 134
Mar 07, 2018: Danaher Provides Update on First Quarter 2018 Financial Performance 135
Jan 30, 2018: Danaher Reports Fourth Quarter And Full Year 2017 Results 136
Oct 19, 2017: Danaher Reports Third Quarter 2017 Results 137
Jul 20, 2017: Danaher Reports Second Quarter 2017 Results 138
Apr 20, 2017: Danaher Reports First Quarter 2017 Results 139
Jan 31, 2017: Danaher Reports Fourth Quarter And Full Year 2016 Results 140
Corporate Communications 141
Apr 25, 2018: Diebold Nixdorf Elects Board Members At Annual Shareholders Meeting 141
Jan 20, 2018: Danaher Announces Transition Plan for Chief Financial Officer 142
Nov 28, 2017: Danaher Announced its Leadership Appointment 143
Feb 21, 2017: Danaher Announces Appointment Of Raymond C. Stevens, Ph.D. To Danaher Board 144
Legal and Regulatory 145
Jul 19, 2018: Danaher announces plan to Spin off dental business into an independent, publicly traded company 145
Appendix 146
Methodology 146
About GlobalData 146
Contact Us 146
Disclaimer 146

List of Tables
Danaher Corp, Medical Equipment, Key Facts, 2017 2
Danaher Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Danaher Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 9
Danaher Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 10
Danaher Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 11
Danaher Corp, Deals By Market, 2012 to YTD 2018 12
Danaher Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 13
Beckman Coulter Acquires Clinical Microbiology Business from Siemens Healthcare Diagnostics 18
Devicor Medical Products Acquires Hydromark Breast Biopsy Marker Portfolio And Related Assets From Biopsy Sciences 20
H2O TECH Secures Investment In Venture Financing 21
Leica Biosystems Enters into Licensing Agreement with Arno Therapeutics 22
Cell Signaling Technology Enters Into Licensing Agreement With Cepheid For Personalized Cancer Diagnostics 23
Smart Imaging Enters Into Licensing Agreement With Leica Microsystems 24
Prosolia Enters Into Licensing Agreement With AB Sciex For ORNL Analytical Technology 25
Thermo Fisher and Leica Microsystems Enter into Partnership 26
AB Sciex Enters into Co-Marketing Agreement with IROA Technologies 27
Leica Biosystems Enters into Distribution Agreement with Kub Technologies 28
Clearbridge Enters into Agreement with Leica Biosystems 29
Clearbridge BioMedics and Leica Biosystems Enter into Co-Marketing Partnership 30
SCIEX forms Joint Venture with Zhejiang Dian Diagnostics in China 31
Nobel Biocare Enters into Agreement with Dentalpoint 32
Grifols and Beckman Coulter Enter into Distribution Agreement 33
SpeeDx Enters into Distribution Agreement with Cepheid 34
Bayer Enters into Co-Development Agreement with Leica Biosystems 35
Novacyt Enters into Partnership with Cepheid 36
DiaSorin Enters into Agreement with Beckman Coulter 37
Devicor Medical Products Enters into Distribution Agreement with Endomagnetics 38
Leica Biosystems Enters into Co-Development Agreement with Merrimack Pharma 39
AB Sciex Enters into Agreement with QPS Holdings 40
Leica Biosystems Enters into Agreement with Advanced Cell Diagnostics 41
Cepheid, MedImmune and Combacte Enter into Agreement 42
AB Sciex Enters into Co-Marketing Agreement with Pressure BioSciences 43
Cepheid Enters into Agreement with Foundation for Innovative New Diagnostics 44
Sidney Kimmel Cancer Center Enters into Agreement with Cepheid 45
RareCyte Enters into Co-Marketing Agreement with Leica Biosystems 46
Vomaris Innovations Enters into Distribution Agreement with Metrex Research 47
DiaSorin Enters into Distribution Agreement with Beckman Coulter Diagnostics 48
Ab Sciex Enters into Co-Marketing Agreement with Hepregen 49
NanoCellect Biomedical Enters into Co-Development Agreement with Invetech 50
Bio-Rad Labs Extends Agreement with Beckman Coulter Diagnostics 51
NeoStem Enters into Co-Development Agreement with Invetech 52
Leica Biosystems Nussloch Partners with NovoPath 53
Leica Biosystems Nussloch Partners with Mayo Clinic 54
Foundation for Innovative New Diagnostics Enters into Agreement with Cepheid and Rutgers 55
Ab Sciex Enters into Co-Development Agreement with Dalton Pharma 56
Leica Biosystems Enters into Co-Marketing Agreement with Advanced Cell Diagnostics 57
Leica Biosystems Enters into Co-Development Agreement with Bristol-Myers Squibb 58
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK 59
Devicor Medical Products Enters Into Distribution Agreement With Faxitron Bioptics For CoreVision 60
Invetech Enters Into Co-Development Agreement With Biocartis For Evalution 61
Arno Therapeutics Enters Into Co-Development Agreement With Leica Biosystems 62
Ab Sciex, Genedata And Leco Enter Into Agreement For Metabolomics Data Analysis Solution 63
Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 64
Leica Biosystems Enters Into Agreement With Aspera For Data Distribution Solution 65
CellaVision Expands Distribution Agreement With Beckman Coulter 66
Leica Biosystems And Synthon Biopharma Enter Into Agreement To Develop Companion Diagnostic Test For Targeted Cancer Therapies 67
Cepheid Enters Into Co-Development Agreement With Oregon Health and Science University 68
Galena Biopharma Enters Into Co-Development Agreement With Leica Biosystems 69
IRIS International Enters Into Distribution Agreement With Alifax 70
Leica Microsystems Enters Into Integration Agreement With Indica Labs 71
Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 72
Radisens Diagnostics Enters Into Co-Development Agreement With Beckman Coulter For HDR Detection Technology 73
Devicor Medical Products Enters Into Co-Marketing Agreement With Carbon Medical Technologies 74
Iris International Enters Into Distribution Agreement With Fisher HealthCare 75
Molecular Devices and ForteBio Complete Merger to Form Biologics Solutions 76
Danaher Plans to Raise Funds through Public Offering of Securities 77
Danaher Raises USD279.8 Million in Public Offering of Floating Rate Notes Due 2022 78
Danaher Raises USD671.6 Million in Public Offering of 1.2% Notes Due 2027 80
Danaher Raises USD500 Million in Public Offering of 1.65% Notes Due 2018 82
Danaher Raises USD500 Million in Public Offering of 3.35% Notes Due 2025 84
Danaher Raises USD500 Million in Public Offering of 2.4% Notes Due 2020 86
Danaher Raises USD500 Million in Public Offering of 4.375% Notes Due 2045 88
Danaher Raises USD500 Million in Public Offering of Notes Due 2017 90
Danaher Raises USD671 Million in Public Offering of 1% Notes Due 2019 92
Danaher Raises USD894.5 Million in Public Offering of 2.5% Notes Due 2025 94
Danaher Raises USD894.5 Million in Public Offering of 1.7% Notes Due 2022 96
Cepheid Completes Private Placement Of Notes Due 2021 For US$345 Million 98
GENEWIZ to Acquire Genomic Services Business of Beckman Coulter 100
Haemonetics Completes Acquisition Of Blood Collection, Filtration And Processing Product Lines From Pall For US$551 Million 101
Danaher to Acquire Integrated DNA Technologies 103
Danaher Acquires Phenomenex 104
Danaher Acquires Cepheid 105
Danaher Acquires Pall for USD13.8 Billion 107
Leica Microsystems to Acquire Bioptigen 109
Danaher Acquires 97% Stake in Nobel Biocare for USD2.17 Billion in Tender Offer 110
Leica Biosystems Nussloch Acquires Devicor Medical from GTCR 112
Leica Biosystems Acquires Kreatech Diagnostics 113
Leica Microsystems And Leica Biosystems Acquire Aotec Instrumentos 114
Quest Diagnostics Completes Sale Of HemoCue To Radiometer Medical For US$300 Million 115
Danaher Completes Acquisition Of 91.6% Stake In Iris International, Diagnostic Test Maker, For US$324 Million 117
Leica Biosystems Completes Acquisition Of Aperio Technologies 119
Beckman Coulter Acquires Blue Ocean Biomedical From Npe Systems 121
Pall Corporation Completes Acquisition Of ForteBio For US$142.5 Million 122
Danaher Corp, Key Competitors 124
Danaher Corp, Key Employees 125
Danaher Corp, Other Locations 126
Danaher Corp, Subsidiaries 126
Danaher Corp, Business Unit 133

List of Figures
Danaher Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Danaher Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Danaher Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Danaher Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Danaher Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 9
Danaher Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 10
Danaher Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 11
Danaher Corp, Medical Equipment, Deals by Market, 2012 to YTD 2018 12

★海外企業調査レポート[Danaher Corp (DHR)：医療機器：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Deli Management, Inc. ：企業の戦略・SWOT・財務情報
    Deli Management, Inc. - Strategy, SWOT and Corporate Finance Report Summary Deli Management, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Sequella Inc-医療機器分野：企業M&A・提携分析
    Summary Sequella Inc (Sequella) is a clinical-stage pharmaceutical company that develops and commercializes small molecule and natural product-based therapeutics for the treatment of infectious diseases. The company’s product pipeline include SQ109, Sutezolid, SQ641 and SQ609; and a novel rapid anti …
  • Olink Proteomics AB-医療機器分野：企業M&A・提携分析
    Summary Olink Proteomics AB (Olink) is a biotechnology company that provides products and services for human protein biomarker research. The company’s portfolio of products includes biomarkers, cardiovascular diseases panels, neurological disease panels, inflammation panels and oncology panels. Olin …
  • Polenergia SA (PEP)：企業の財務・戦略的SWOT分析
    Polenergia SA (PEP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Cell Signaling Technology Inc：医療機器：M&Aディール及び事業提携情報
    Summary Cell Signaling Technology Inc (CST) is a biological research and diagnostic products provider. The company offers primary antibodies, antibody samplers, secondary antibodies, antibody conjugates, elisa kits, chip kits and reagents proteomic analysis products, cellular assay kits, WB and IP r …
  • Recondo Technology Inc：医療機器：M&Aディール及び事業提携情報
    Summary Recondo Technology Inc (Recondo) is a provider of cloud-based software and services that streamline operations in the healthcare industry. The company provides Empowered Patient Access, Empowered Business Office, and Empowered Technology solutions to connect providers with payers and their p …
  • bioLytical Laboratories Inc：製品パイプライン分析
    Summary bioLytical Laboratories Inc (bioLytical) is a medical device company that develops and manufactures HIV diagnostic products. The company offers products such as insti HIV-1/HIV-2 antibody test and insti HIV-1/HIV-2 test controls. Its product line provides test results that translates into a …
  • Phoenix Global Resources Plc (PGR)：企業の財務・戦略的SWOT分析
    Phoenix Global Resources Plc (PGR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Sheraton Seoul Palace：企業の戦略・SWOT・財務分析
    Sheraton Seoul Palace - Strategy, SWOT and Corporate Finance Report Summary Sheraton Seoul Palace - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Tokyo Printing Ink Mfg Co Ltd (4635)
    Tokyo Printing Ink Mfg Co Ltd (4635) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Pharmsynthez (LIFE)：製薬・医療：M&Aディール及び事業提携情報
    Summary Pharmsynthez is a pharmaceutical company that manufactures and markets generic active pharmaceutical ingredients. The company offers production and sales of both officinal medicines (original OM) and active pharmaceutical ingredients (API). It offers drugs such as vazostenon, glaumax, cathal …
  • Magnetek Inc：企業の戦略的SWOT分析
    Magnetek Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Jardine Lloyd Thompson Group plc：企業の戦略・SWOT・財務分析
    Jardine Lloyd Thompson Group plc - Strategy, SWOT and Corporate Finance Report Summary Jardine Lloyd Thompson Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • QPS Holdings LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary QPS Holdings LLC (QPS) is a contract research organization that offers bioanalytical contract services. The organization’s services include neuropharmacology, toxicology, DMPK, bioanalysis, translational medicine, clinical development, clinical research, and dermal and transdermal research s …
  • DSG Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary DSG Inc (DSG) is a provider of eClinical software solutions. The company offers software products such as eCaseLink EDC, eClinDirect CTMS, eCaseLink.Me ePRO, DSG Drug Safety, eCaseLink IRT, DSG Designer, CaseXport, CaseView Imaging, and others. Its services include data management, technolog …
  • CytRx Corp (CYTR)：製薬・医療：M&Aディール及び事業提携情報
    Summary CytRx Corp (CytRx) is a clinical state is a biopharmaceutical company focusing on the research and development of novel treatments for cancer. The company’s oncology based product comprises of its lead drug product candidate, aldoxorubicin (formerly INNO-206). Aldoxorubicin is a pro-drug of …
  • Air France-KLM SA：戦略・SWOT・企業財務分析
    Air France-KLM SA - Strategy, SWOT and Corporate Finance Report Summary Air France-KLM SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Genmab AS (GMAB)：企業の財務・戦略的SWOT分析
    Genmab AS (GMAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • MallInckrodt Plc (MNK)：製薬・医療：M&Aディール及び事業提携情報
    Summary Mallinckrodt Plc (Mallinckrodt) is develops, produces, commercializes, and distributes specialty pharmaceutical therapies and products. The company offers both branded and specialty generics for autoimmune and rare diseases in the specialty therapeutic areas of rheumatology, nephrology, neur …
  • Coppermoly Limited：企業の戦略・SWOT・財務情報
    Coppermoly Limited - Strategy, SWOT and Corporate Finance Report Summary Coppermoly Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆